Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SPRY

ARS Pharmaceuticals Inc

Sep 13 • 04:00PM ET

13.30

Dollar change +0.67
Percentage change 5.30	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF IWO DWAS IBB SCHA VTWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.47	Insider Own	49.81%	Shs Outstand	96.41M	Perf Week	17.08%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-0.86	Insider Trans	-5.86%	Shs Float	48.66M	Perf Month	2.31%
Income	-44.84M	PEG	-	EPS next Q	-0.14	Inst Own	38.13%	Short Float	22.52%	Perf Quarter	48.77%
Sales	0.50M	P/S	2578.60	EPS this Y	-12.72%	Inst Trans	15.31%	Short Ratio	10.36	Perf Half Y	47.78%
Book/sh	2.22	P/B	5.99	EPS next Y	-33.85%	ROA	-18.66%	Short Interest	10.96M	Perf Year	79.73%
Cash/sh	2.26	P/C	5.89	EPS next 5Y	-	ROE	-19.34%	52W Range	2.55 - 16.50	Perf YTD	142.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.44%	ROI	-20.83%	52W High	-19.39%	Beta	0.89
Dividend TTM	-	Quick Ratio	32.78	Sales past 5Y	-34.76%	Gross Margin	87.60%	52W Low	421.57%	ATR (14)	0.80
Dividend Ex-Date	-	Current Ratio	32.78	EPS Y/Y TTM	80.81%	Oper. Margin	-11347.20%	RSI (14)	59.20	Volatility	5.47% 6.67%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-8968.40%	Recom	1.00	Target Price	24.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	29.34%	Payout	-	Rel Volume	1.14	Prev Close	12.63
Sales Surprise	-50.00%	EPS Surprise	-17.54%	Sales Q/Q	4900.00%	Earnings	Aug 06 AMC	Avg Volume	1.06M	Price	13.30
SMA20	3.56%	SMA50	15.51%	SMA200	53.64%	Trades		Volume	1,209,432	Change	5.30%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
10:08AM	Loading…
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Aug-22-24 12:27AM	ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares (GuruFocus.com)
Aug-20-24 12:21PM	ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst (Benzinga)
Aug-15-24 07:02PM	Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY) (GuruFocus.com)
Aug-12-24 04:32AM	ARS Pharmaceuticals anaphylaxis nasal spray gains FDA approval (Pharmaceutical Technology)
Aug-09-24 01:34PM	FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment (Benzinga) +10.01%
12:49PM	ARS Pharmaceuticals Receives FDA Approval of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-07-24 09:01AM	ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-06-24 05:20PM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-28-24 06:30AM	ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire) +5.71%
May-12-24 09:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ... (GuruFocus.com)
May-09-24 11:54PM	SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 (InvestorPlace)
04:05PM	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 09:01AM	ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand (GlobeNewswire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 09:01AM	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) (GlobeNewswire)
Apr-01-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know (Zacks) -7.34%
Mar-26-24 08:50AM	Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why (Zacks) +9.53%
Mar-21-24 10:53PM	SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-15-24 06:00AM	Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 (InvestorPlace)
04:05PM	Loading…
Mar-07-24 04:05PM	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day (GlobeNewswire)
Mar-06-24 09:01AM	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 09:01AM	ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study (GlobeNewswire)
Feb-22-24 09:01AM	ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024 (GlobeNewswire)
Feb-20-24 09:01AM	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter (GlobeNewswire)
Feb-05-24 09:01AM	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +8.75%
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-21-23 12:28PM	ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray (Zacks) +25.68%
10:43AM	Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down (Zacks)
06:28AM	Feds Message Is Louder Than Its Rate Call. Why Thats Critical for Investors. (Barrons.com)
Sep-20-23 12:42PM	Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday (Motley Fool) -55.79%
10:31AM	FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies (AP Finance)
10:26AM	FDAs Surprise Rejection of No-Shot Alternative to EpiPen Halves Shares of ARS Pharma (Barrons.com)
09:49AM	FDA Declines to Approve Epinephrine Nasal Spray, Asks for Additional Data (The Wall Street Journal)
06:13AM	ARS Pharma shares plummet after FDA asks for extra test of nasal spray (Investing.com)
Sep-19-23 10:49PM	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study (GlobeNewswire) -11.22%
Sep-08-23 07:10PM	Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investors (Barrons.com)
Aug-10-23 04:00PM	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-20-23 08:00AM	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-15-23 02:11PM	ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray (Zacks)
09:00AM	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 11:51AM	Why ARS Pharmaceuticals Stock Is Soaring Today (Benzinga) +77.88%
May-11-23 07:01PM	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-09-23 09:10AM	ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire) -14.31%
Apr-21-23 10:05AM	Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-28-23 09:39AM	ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
Mar-25-23 09:10AM	ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-23-23 04:01PM	ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-22-23 06:19AM	One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year (Simply Wall St.) -5.56%
Feb-23-23 04:01PM	ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors (GlobeNewswire)
Feb-22-23 04:05PM	ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire)
Feb-09-23 06:30AM	ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 (GlobeNewswire) +5.76%
05:43AM	Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company (Simply Wall St.)
Nov-10-22 08:00AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:24 PM
Lowenthal Richard E	Officer	Sep 10 '24	Proposed Sale	11.36	300,000	3,408,000		Sep 10 10:31 AM
Thompson Peter A.	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:30 PM
ORBIMED ADVISORS LLC	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:26 PM
Thompson Peter A.	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:41 PM
ORBIMED ADVISORS LLC	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:38 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Option Exercise	0.64	50,000	32,000	56,024	Aug 21 06:51 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Sale	15.00	50,000	750,000	6,024	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Option Exercise	1.50	10,000	15,000	15,693	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Sale	14.00	10,000	140,000	5,693	Aug 21 06:51 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Option Exercise	1.50	12,500	18,750	25,699	Aug 21 06:49 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Sale	16.00	12,500	200,000	13,199	Aug 21 06:49 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:48 PM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:47 PM
OrbiMed Partners Master Fund L	Shareholder	Aug 21 '24	Proposed Sale	14.89	952,377	14,180,894		Aug 21 06:43 PM
KATHLEEN D SCOTT	Officer	Aug 20 '24	Proposed Sale	16.00	12,500	200,000		Aug 20 04:18 PM
BRIAN T DORSEY	Officer	Aug 20 '24	Proposed Sale	15.00	50,000	750,000		Aug 20 04:05 PM
ERIC KARAS	Officer	Aug 19 '24	Proposed Sale	14.00	10,000	140,000		Aug 19 04:17 PM
Dorsey Brian	Chief Operating Officer	Aug 13 '24	Option Exercise	0.64	30,000	19,200	36,024	Aug 15 04:30 PM
Dorsey Brian	Chief Operating Officer	Aug 13 '24	Sale	13.00	30,000	390,000	6,024	Aug 15 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 13 '24	Sale	12.48	100,000	1,247,555	1,446,494	Aug 15 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 13 '24	Sale	12.48	100,000	1,247,555	1,446,494	Aug 15 04:30 PM
BRIAN T DORSEY	Officer	Aug 13 '24	Proposed Sale	13.00	30,000	390,000		Aug 13 05:02 PM
Lowenthal Richard E	PRESIDENT AND CEO	Jul 16 '24	Sale	11.40	100,000	1,140,295	1,547,447	Jul 18 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jul 16 '24	Sale	11.40	100,000	1,140,295	1,547,447	Jul 18 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jul 09 '24	Sale	9.62	100,000	961,725	1,496,494	Jul 11 05:04 PM
Lowenthal Richard E	PRESIDENT AND CEO	Jul 09 '24	Sale	9.62	100,000	961,725	1,496,494	Jul 11 05:03 PM
Lowenthal Richard E	PRESIDENT AND CEO	Jun 12 '24	Sale	9.15	95,862	876,663	1,546,494	Jun 13 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Jun 11 '24	Sale	9.00	4,138	37,254	1,594,328	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jun 12 '24	Sale	9.15	95,862	876,663	1,546,494	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jun 11 '24	Sale	9.00	4,138	37,254	1,594,328	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 16 '24	Sale	9.06	89,096	807,023	1,597,447	May 16 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 14 '24	Sale	9.01	5,757	51,854	1,644,574	May 16 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 15 '24	Sale	9.05	5,147	46,565	1,642,193	May 16 07:52 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 16 '24	Sale	9.06	89,096	807,023	1,597,447	May 16 07:51 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 14 '24	Sale	9.01	5,757	51,854	1,644,574	May 16 07:51 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 15 '24	Sale	9.05	5,147	46,565	1,642,193	May 16 07:51 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 07 '24	Sale	9.34	100,000	934,365	1,596,494	May 09 06:59 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 07 '24	Sale	9.34	100,000	934,365	1,596,494	May 09 06:57 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 23 '24	Option Exercise	1.06	130,993	138,990	3,407,847	Apr 24 06:18 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 23 '24	Option Exercise	1.06	130,993	138,990	3,407,847	Apr 24 06:17 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 19 '24	Option Exercise	1.06	188,491	199,999	4,315,313	Apr 22 07:23 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 19 '24	Option Exercise	1.06	188,491	199,999	4,315,313	Apr 22 07:22 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 16 '24	Sale	9.28	100,000	928,005	1,647,447	Apr 17 06:42 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 16 '24	Sale	9.28	100,000	928,005	1,647,447	Apr 17 06:40 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 09 '24	Sale	9.28	100,000	927,735	1,646,494	Apr 10 05:39 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 09 '24	Sale	9.28	100,000	927,735	1,646,494	Apr 10 05:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '24	Buy	9.79	505,954	4,953,290	9,958,073	Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 26 '24	Buy	9.55	457,745	4,371,465	9,452,119	Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 25 '24	Buy	9.06	437,600	3,964,656	8,994,374	Mar 27 07:37 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 25 '24	Sale	9.12	95,267	869,188	1,697,447	Mar 26 06:48 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 22 '24	Sale	9.02	2,343	21,135	1,745,082	Mar 26 06:48 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 25 '24	Sale	9.12	95,267	869,188	1,697,447	Mar 26 06:47 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	9.02	2,343	21,135	1,745,082	Mar 26 06:47 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 19 '24	Sale	9.03	1,918	17,324	1,746,471	Mar 21 09:51 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 21 '24	Sale	9.00	472	4,248	1,746,099	Mar 21 09:51 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 19 '24	Sale	9.03	1,918	17,324	1,746,471	Mar 21 09:50 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 21 '24	Sale	9.00	472	4,248	1,746,099	Mar 21 09:50 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 15 '24	Sale	9.14	96,756	884,485	1,696,494	Mar 15 07:55 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 13 '24	Sale	9.00	2,800	25,200	1,744,994	Mar 15 07:55 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 14 '24	Sale	9.00	444	3,996	1,744,789	Mar 15 07:55 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 15 '24	Sale	9.14	96,756	884,485	1,696,494	Mar 15 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 13 '24	Sale	9.00	2,800	25,200	1,744,994	Mar 15 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 14 '24	Sale	9.00	444	3,996	1,744,789	Mar 15 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 29 '24	Sale	9.02	3,782	34,101	1,746,494	Mar 01 08:21 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 29 '24	Sale	9.02	3,782	34,101	1,746,494	Mar 01 08:17 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 28 '24	Sale	9.02	98,778	891,061	1,747,294	Feb 28 09:08 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 26 '24	Sale	9.01	700	6,307	1,772,750	Feb 28 09:08 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 28 '24	Sale	9.02	98,778	891,061	1,747,294	Feb 28 09:04 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 26 '24	Sale	9.01	700	6,307	1,772,750	Feb 28 09:04 PM
Fitzpatrick Alexander A	Chief Legal Officer	Sep 29 '23	Buy	3.78	46,258	174,994	89,227	Oct 02 04:23 PM
Fitzpatrick Alexander A	Chief Legal Officer	Sep 28 '23	Buy	3.62	40,000	144,960	42,969	Oct 02 04:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 21 '23	Buy	3.03	2,700,000	8,183,526	8,556,774	Sep 25 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRY

ARS Pharmaceuticals Inc

Upgrade your FINVIZ experience